BioRev

Rice Peptide

RICE PEPTIDE

Peptide nutrition derived from rice

Product & technology guide / Customer edition



Product preview · Packaging illustration · Distributed by BioRev

Product overview

Plant-derived ingredients, peptide research and individual sachets

Product	BioRev Rice Peptide
Core ingredient concept	Polimi / PM rice peptides
Format	Powder in individually sealed sachets
Specifications	4 g × 20 sachets; net weight 80 g
Packaging	Textured white gift box with matte-gold rice ears
Distributor	BioRev
Retail price	CNY 1,680 / box

Product preview. The final product determines the formula, category and labelling.

From ingredient research to everyday experience

01

Rice-derived

Research on Polimi No. 1 rice protein
and its peptide components,
with a clearly traceable ingredient origin.

02

Intellectual property

Plant variety rights and two
Chinese invention patents cover the variety,
composition process and small-peptide research.

03

Individual sachets

Easy to use and carry.
A white and matte-gold gift box,
for everyday use or thoughtful gifting.

Technology and IP belong to the ingredient technology providers. Research is presented for its original study subjects.

The origin: Polimi No. 1 rice

The technology provider progressed from rice protein to peptide research

Variety: Polimi No. 1
Species: Rice

Period	Progress described by the technology provider
2017–2018	Variety development and early observations
2019–2021	Protein components and peptide composition research
From 2022	Candidate peptide screening and related patent applications



Timeline compiled from the provider's ingredient materials. The rice imagery is illustrative, not a photograph of its growing site.

Plant variety rights

Polimi No. 1

CNA20181039.9

Rights holder
Guangdong Polimi Biotechnology Co., Ltd.

Granted: 18 August 2022


植物新品种权证书

品种名称： 普立米1号

属或者种： 水稻

品种权人： 广东普立米生物科技有限公司

培 育 人： 张希彤 宋永玉

品种权号： CNA20181039.9

申 请 日： 2018年3月27日

授 权 日： 2022年8月18日

证书号： 第 2022021145 号

The certificate relates to the ingredient variety. Image reproduced from the original supplied by the technology provider.

Three IP rights across ingredients and technology

Plant variety rights + two Chinese invention patents







Ingredient variety

CNA20181039.9

Composition process

CN115521962B

Small-peptide research

CN117720618B

Variety rights: Guangdong Polimi Biotechnology Co., Ltd. Both patents: Furuishi Biomedical Technology (Shenzhen) Co., Ltd.

Rice peptide composition patent

Rice peptide composition, its preparation method and applications

Publication number: CN115521962B
Patent number: ZL 2022 1 1172996.5
Grant publication date: 15 March 2024


证书号第6791568号

发明专利证书

发 明 名 称：水稻多肽组合物及其制备方法和应用

发 明 人：张希彤;尹小建

专 利 号：ZL 2022 1 1172996.5

专利申请日：2022年09月26日

专 利 权 人：福瑞施生物医药科技（深圳）有限公司

地 址：518000 广东省深圳市前海深港合作区前湾一路1号A栋201

授权公告日：2024年03月15日 授权公告号：CN 115521962 B

国家知识产权局依照中华人民共和国专利法进行审查，决定授予专利权，颁发发明专利证书并在专利登记簿上予以登记。专利权自授权公告之日起生效。专利权期限为二十年，自申请日起算。

专利证书记载专利权登记时的法律状况。专利权的转移、质押、无效、终止、恢复和专利权人的姓名或名称、国籍、地址变更等事项记载在专利登记簿上。

局长
申长雨

国家知识产权局
2024年03月15日

第1页(共2页)

其他事项参见续页

Patent holder
Furuishi Biomedical Technology (Shenzhen) Co., Ltd.

The patent concerns preparation and application research. A patent grant is not approval of finished-product efficacy.

Two-stage hydrolysis and ultrafiltration

Overview of the preparation route described in the patent

01

Pretreatment

Rice seeds undergo pretreatment before enzymatic hydrolysis.

→

02

First-stage hydrolysis

Protein components undergo the first hydrolysis stage.

→

03

Second-stage hydrolysis

Hydrolysis continues after the first stage.

→

04

Ultrafiltration

Ultrafiltration separates the rice peptide composition.

Composition characteristics depend on the preparation process

Schematic based on the provider's materials and the published patent; it illustrates the technology route.

Protein, compositions and small peptides: research levels

Level	Meaning in this brochure	Key focus
Rice protein	Protein components derived from rice	Ingredient origin and research starting point
Peptide composition	Peptide mixture obtained by hydrolysis and separation	Preparation and composition research
Specific small peptides	Particular peptide sequences selected for further study	Candidate peptides such as P1 and P2

10kD Ultrafiltration parameter in the technical materials, not the peptide amount per sachet

Separation parameters, experimental codes and finished-product label quantities are different types of information.

The second invention patent: small peptides

A small peptide and its application in mucosal repair

Publication number: CN117720618B
Patent number: ZL 2023 1 1255096.1
Grant publication date: 18 October 2024



Patent holder
Furuishi Biomedical Technology (Shenzhen) Co., Ltd.

“Mucosal repair” is the patent title and research subject, not an approved efficacy claim for the BioRev finished product.

From peptide compositions to P1 and P2 research

P1 / P2

Codes for candidate small peptides in the provider's research

Researchers analyse and screen peptides,
then observe their behaviour in experimental models.

Peptide analysis

Compare peptide components

Candidate screening

Focus on specific sequences

Model observations

Study mucosa-related outcomes

Source: the small-peptide patent and provider's brochure. No BioRev sachet P1/P2 content or human effects are inferred.

ZO-1: observing cell tight-junction-related changes

Immunofluorescence images supplied by the technology provider

ZO-1

A protein associated with cell tight junctions

The images compare controls, alcohol exposure and conditions with added P1/P2.
Green indicates ZO-1-related signals;
blue indicates nuclear staining.




Image: provider's Taiheyuan Product Brochure, p. 5. Experimental model results, not human evidence for the BioRev finished product.

Research areas and study subjects

Studies use different formulations, populations or models

Area	Subjects in the original materials	Main observations
Oral mucosa	Original liquid; radiotherapy-related mucositis patients	Lesions, grades, pain and photographs
Oesophageal mucosa	Original composition solution; thoracic radiotherapy patients	Cases by oesophagitis grade
Gastric mucosa	Acute injury model in rats	Ulcer index and model outcomes
Gastrointestinal function	Participants observed using the original rice peptide composition	Symptom assessment and category results

The following studies concern the provider's ingredients, original products or models, not clinical validation of BioRev powder.

Oral observations: 40 people over 7 days

People with radiotherapy-related oral mucositis

40 people

20 people in each group
Randomisation stated in the source

Changes in ulcer area were observed and original efficacy categories recorded


Group	Original study regimen
Experimental group	Polimi peptide liquid
Control group	Kangfuxin liquid + 4% sodium bicarbonate
Observation points	Before intervention and day 7

Original liquid study; provider's materials state “results pending publication”. This is not a BioRev powder clinical trial.

Oral observations: all category results

Number of people / 20 in each group

Group	Healed	Marked response	Response	No response
Polimi liquid	5	12	3	0
Control	0	2	6	12



Polimi group: 5 + 12 + 3 = 20 people
Control group: 0 + 2 + 6 = 8 people

Meeting response criteria includes healed, marked response and response; it does not mean all were cured. Original liquid results, not BioRev effects.

What do 20/20 and 8/20 mean?

20 / 20

Polimi group meeting the original response criteria

8 / 20

Control group meeting the original response criteria

Original category	Criteria stated in the source
Response	Ulcer area reduced by 50%
Marked response	Ulcer area reduced by 75%
Healed	Lesion healed and surface smooth again

Small-sample observation of the original liquid; results pending publication. Not a personal guarantee or a BioRev powder cure rate.

Original product case A: images on day 6

Male, 48 · During radiotherapy for nasopharyngeal cancer · Oral mucosa

Source record: before intervention, WHO oral mucositis grade 3; VAS pain score 5.



Before intervention



Day 6

Source: Jiashukang—Dongguan People's Hospital Radiotherapy Department, p. 14. Original liquid case images, not BioRev efficacy or anticancer results.


Original product case B: days 5 and 7

Female, 62 · Chemoradiotherapy for nasopharyngeal cancer · Oral mucosa

Source record: before intervention, WHO oral mucositis grade 4; VAS pain score 7.



Before intervention



Day 5




Day 7

Source: Jiashukang—Dongguan People's Hospital Radiotherapy Department, pp. 15–16. Follow-up of one original-product case; not transferable to BioRev.

Original product case C: different sites on day 7

Male, 51 · Chemoradiotherapy for nasopharyngeal cancer

Source record: before intervention, WHO oral mucositis grade 4; VAS pain score 6.

Before intervention		Day 7	
			
Site 1	Site 2	Site 1	Site 2

Source: Jiashukang—Dongguan People's Hospital Radiotherapy Department, pp. 17–18. One original-product case, not two independent studies or a BioRev trial.

Original product case D: images on day 1

Male, 69 · During chemotherapy for lung cancer · Oral mucosa

Source record: before intervention, WHO oral mucositis grade 2; VAS pain score 4, with difficulty eating.



Before intervention




Day 1

Source: Jiashukang—Dongguan People's Hospital Radiotherapy Department, p. 19. “Day 1” is the photo time, not a promise of effects within one day.

Oesophageal observations: cases by grade

60 thoracic radiotherapy patients · 2 months · Original composition solution

Group	Grade 1	Grade 2	Grade 3
Experimental	7	2	0
Control	20	8	1




The source reports fewer higher-grade cases in the experimental group.

Group totals are not specified on the supplied page, so incidence rates are not calculated. Original-product observations, not BioRev powder results.

Gastric mucosa research: acute injury in rats

6 rats per group · Provider's original peptide liquid experiment

Group	Ulcer index (%)
Distilled-water control	61.2 ± 13.1
Original peptide liquid	12.9 ± 7.7



78.9%

Ulcer inhibition rate reported in the source

Chart shows means; “±” is retained as reported. Animal-model results cannot be directly extrapolated to humans or the BioRev finished product.

Gastrointestinal observations: all original categories

Original rice peptide composition · 120 participants

Group	People	Marked response	Response	No response
Group A	66	39	20	7
Group B	54	0	1	53

Assessment: an efficacy index based on changes in symptom scores before and after treatment. The source also reports GSRS gastrointestinal symptom score observations.

The source total responders differ from category sums, so no overall response rate is shown. Original category data, not BioRev finished-product results.

Food manufacturing licence documents

Guangdong Suyuan Traditional Chinese Medicine Industry Co., Ltd.

SC10644180213884

Licensed categories include solid beverages (0606), including protein-based solid beverages.

Issued: 3 August 2026
Valid until: 4 December 2030
Issuer: Qingyuan Administration for Market Regulation



食 品 生 产 许 可 证

生产者名称：广东素源中医药实业有限公司　　许 可 证 编 号：SC10644180213884

法定代表人（负责人）：陈亮　　统一社会信用代码：91441802MAE3D8TW4E

住　　所：广东省清远市清城区石角镇广清经济特别合作区广清产业园黄埔三路6号（一址多照）

生 产 地 址：广东省清远市清城区石角镇广清经济特别合作区广清产业园黄埔三路6号

食 品 类 别：饮料;糖果制品

发证机关：清远市市场监督管理局

发 证 日 期：2026 年 8 月 3 日

有效日期至：2030 年 12 月 4 日

国家市场监督管理总局监制

Shown from the factory's licence and category list. The licensed entity is retained as named in the original document.

FDA food facility registration documents

Registration number: 10607884292

Entity named in the document
Guangdong Jiasuweilai Zhongyiyao Industry Co., Ltd.

Guangdong Jiasuweilai Zhongyiyao
Industry Co., LTD

Document states validity until 31 December 2026
US agent: UGK-LVM UNITED INC.



FDA FFR | FOOD FACILITY REGISTRATION
Fiscal Year 2025-2026

This certifies that:

Guangdong Jiasuweilai Zhongyiyao Industry Co., LTD

Building 1,No. 6, Huangpu 3rd Road, Guangqing Industrial Park, Guangqing Economic Special Cooperation Zone, Shijiao Town, Qingcheng District, qingyuan, Guangdong, 511500, CHINA.

is registered with the U.S. Food and Drug Administration pursuant to section 305 of the United States Public Health Security and Bioterrorism Preparedness and Response Act of 2002, P.L.107-188, such registration having been verified as currently effective on the date here of by OUA

U.S. FDA Registration No. : **10607884292**
U.S. Registration Agent : **UGK-LVM UNITED INC.**
D-U-N-S Number : **554905577**

This certificate affirms that the above stated facility is registered with the U.S. Food and Drug Administration pursuant to section 305 of the U.S. Public Health Security and Bioterrorism Preparedness and Response Act of 2002, P.L. 107-188, such registration having been verified as effective by OUA as of the date hereof, and OUA will confirm that such registration remains effective upon request and presentation of this certificate until the expiration of one year from the date hereof, unless terminated after issuance of this certificate. OUA makes no other presentations or warranties, nor does this certificate make any representations or warranties to any person or entity other than the named certificate holder, for whose sole benefit it is issued. OUA assume no liability to any person or entity in connection with the foregoing. The U.S. Food and Drug Administration does not issue a certificate of registration, nor does the U.S. Food and Drug Administration recognize a certificate of registration. OUA is not affiliated with the U.S. Food and Drug Administration.

Shenzhen OUA Testing Technology Co., Ltd.
W: www.fda-test.com E: fda@fda-test.com
T: 400-8788-298 T: 86-755-23245357

Luna Zhu/Chief engineer
Issued: 04/08/2026
Expiration Date: 12/31/2026

Shenzhen OUA Testing Technology Co., Ltd. OUA Approved

Third-party document; the registered entity differs from the SC licensee. Food facility registration is not FDA product approval or efficacy certification.

20 individually sealed sachets in one box

20 sachets / box

4 g / sachet
Net weight: 80 g



Individual portions · Easy to carry

Packaging illustration. 4 g is the finished-product net weight per sachet; ingredients and peptide quantities are subject to the final label.

Rice peptides in your everyday routine

At home

Individual sachets for convenient use

At work and on the go

Easy to carry; prepare as directed on the label



Drink and packaging illustrations. Water quantity, temperature and consumption frequency are subject to the final product label.

White and matte gold: a thoughtful gift

BioRev rice-ear themed gift box

White texture and rice ears

Rice imagery reflects the ingredient origin,
paired with matte-gold BioRev lettering.

An everyday choice

For yourself or someone you care about.
Gift bags and accessories may be selected with the order.



Gift packaging illustration. Bags, cards and other accessories are subject to order confirmation.

Frequently asked questions

Is each sachet 4 g of pure peptides?

4 g is the finished-product net weight. Ingredient quantities are subject to the final label.

Do these studies concern this box of product?

The studies concern the provider's ingredients, original liquid products or experimental models.

How many sachets should I take daily?

Follow the finished-product label, not the liquid regimens used in the studies.

Can it replace medication?

A food powder cannot replace prescribed treatment.

If receiving treatment or needing dietary changes, consult your treating healthcare professional before use.

BioRev Rice Peptide: product and price

Retail price

1,680 CNY / box

4 g × 20 sachets / Net weight 80 g

Equivalent to CNY 84 per sachet, based on 20 sachets

Distributor

BioRev

Contact us for product information and orders

Prices in CNY. Product preview; delivery, taxes, shipping and accessories are subject to order confirmation.

Discover your first box of rice peptides

Rice-derived · Patent research background · Individual sachets · Matte-gold gift box

Contact BioRev for product information and orders

References

Original materials and published patent entries

Content	Source
Variety, process and patents	Polimi Peptide Ingredient Project Introduction, pp. 6, 8–9 Taiheyuan Product Brochure, pp. 4–5, 8
Research data and original-product cases	Polimi Peptide Ingredient Project Introduction, pp. 11–19 Jiashukang—Dongguan Hospital Radiotherapy, pp. 10, 12, 14–20
Manufacturing licence and facility registration	Guangdong Suyuan TCM Industry Co., Ltd., pp. 3–5 Guangdong Jiasuweilai TCM Industry: food FDA registration document
Product specifications and price	Jiashukang—Dongguan Hospital Radiotherapy, p. 22 BioRev Channel Pricing and Cost Estimates · Matte-Gold Edition

Published patents: CN115521962B / CN117720618B
Research data refer to their original subjects. Product information is subject to the final finished product.